Clearside Biomedical's CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating with $5 Price Target
Clearside Biomedical (CLSD Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H...
TipRanks Financial Blog·1y ago